Related Experiment Video

Updated: Jul 14, 2026

Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
11:10

Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation

Published on: July 6, 2022

FMR1 alleles in Parkinson's disease: relation to cognitive decline and hallucinations, a longitudinal study

Martin Wilhelm Kurz1, Anna Melissa Schlitter, Yvonne Klenk

  • 1Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany. kurzmartin@gmx.net

Journal of Geriatric Psychiatry and Neurology
|June 6, 2007
PubMed

Insights

Fragile X gene carriers may show Parkinson's symptoms. This study found no significant link between FMR1 gene CGG repeats and Parkinson's disease progression, though two cases suggest a possible cognitive decline association.

Area of Science:

  • Neurogenetics
  • Neurology
  • Human Genetics

Background:

  • Expanded alleles of the fragile X mental retardation (FMR1) gene are associated with neurological and behavioral changes.
  • Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting motor function.
  • The potential link between FMR1 gene variations and PD requires further investigation.

Purpose of the Study:

  • To investigate the association between CGG repeat lengths in the FMR1 gene and Parkinson's disease.
  • To determine if FMR1 gene repeat size correlates with cognitive decline or hallucinations in PD patients.

Main Methods:

  • Screening of 137 male Parkinson's disease patients for FMR1 gene CGG repeat lengths.
  • Comparison of repeat lengths in PD patients with 310 healthy controls.
  • Longitudinal follow-up of 56 PD patients to assess cognitive decline and hallucinations in relation to CGG repeat size.

Main Results:

  • No significant difference in the proportion of intermediate-size (41-54 CGG repeats) or premutation (55-200 CGG repeats) FMR1 gene carriers between PD patients and controls.
  • Linear regression analysis showed no relationship between the number of CGG repeats and motor or cognitive progression in PD patients.
  • Two patients with intermediate-size FMR1 alleles experienced marked cognitive decline, suggesting a potential, albeit unconfirmed, association.

Conclusions:

  • The study found no significant association between FMR1 gene CGG repeat lengths and Parkinson's disease.
  • A possible link between intermediate-size FMR1 alleles and cognitive decline in PD warrants further investigation.
  • Larger sample sizes are needed to confirm or refute the potential association in future studies.

More Related Videos

Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia13:08

Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia

Published on: December 2, 2015

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...